GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 45,806 Shares
by Renee Jackson · The Cerbat GemGRAIL, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $2,286,635.52. Following the completion of the sale, the chief financial officer owned 260,669 shares of the company’s stock, valued at approximately $13,012,596.48. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Aaron Freidin also recently made the following trade(s):
- On Monday, March 9th, Aaron Freidin sold 2,492 shares of GRAIL stock. The stock was sold at an average price of $47.89, for a total value of $119,341.88.
- On Thursday, March 5th, Aaron Freidin sold 655 shares of GRAIL stock. The stock was sold at an average price of $53.01, for a total value of $34,721.55.
- On Monday, March 2nd, Aaron Freidin sold 9,573 shares of GRAIL stock. The stock was sold at an average price of $50.17, for a total value of $480,277.41.
GRAIL Trading Down 6.3%
GRAL stock traded down $3.22 during mid-day trading on Thursday, reaching $47.56. The company’s stock had a trading volume of 901,496 shares, compared to its average volume of 1,270,402. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -4.25 and a beta of 4.62. The business’s 50 day moving average price is $66.02 and its 200 day moving average price is $79.75. GRAIL, Inc. has a 12 month low of $21.80 and a 12 month high of $118.84.
GRAIL (NASDAQ:GRAL – Get Free Report) last issued its earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. The business had revenue of $43.60 million during the quarter, compared to the consensus estimate of $43.33 million. GRAIL had a negative return on equity of 17.11% and a negative net margin of 277.46%. As a group, equities analysts expect that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. Robert W. Baird set a $82.00 target price on GRAIL in a report on Friday, February 20th. Canaccord Genuity Group lowered their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a report on Friday, February 20th. Morgan Stanley decreased their price objective on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, TD Cowen upgraded GRAIL from a “hold” rating to a “buy” rating and set a $65.00 price objective for the company in a report on Wednesday, March 18th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $72.83.
View Our Latest Research Report on GRAL
Institutional Investors Weigh In On GRAIL
Hedge funds and other institutional investors have recently modified their holdings of the company. N.E.W. Advisory Services LLC bought a new stake in shares of GRAIL during the fourth quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of GRAIL during the fourth quarter valued at approximately $28,000. Elyxium Wealth LLC bought a new stake in shares of GRAIL during the fourth quarter valued at approximately $31,000. Comerica Bank increased its holdings in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after acquiring an additional 173 shares in the last quarter. Finally, Intesa Sanpaolo S.p.A. bought a new stake in shares of GRAIL during the fourth quarter valued at approximately $44,000.
GRAIL Company Profile
GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.
Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.